GlassScriptPhysician profile
Nipun Bhandari
NPI 1043707805
$5,482.77
in general payments reported to CMS, 2019-2025
16 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $549 · 2022: $1,414 · 2023: $2,110 · 2024: $1,298 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,520.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,117.20 | 2022-2024 | Watchman Flx, Avvigo Guidance System, Opticross |
| Shockwave Medical, INC | $1,086.04 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Biotronik INC. | $929.25 | 2021-2024 | Acticor 7 Vr-T Dx, Edora 8 Dr-T |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $698.19 | 2022-2024 | Lifevest |
| Abbott Laboratories | $310.38 | 2022-2023 | Dragonfly Opstar |
| Amgen INC. | $272.25 | 2023 | Repatha |
| Abiomed | $145.21 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $140.80 | 2021-2024 | Camzyos |
| Teleflex LLC | $140.45 | 2024 | Turnpike |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.34 | 2021 | |
| Philips North America LLC | $123.15 | 2023 | |
| Janssen Pharmaceuticals, INC | $122.31 | 2021 | |
| Pfizer INC. | $113.91 | 2022-2023 | |
| Chiesi USA, INC. | $112.00 | 2025 | Kengreal |
| Heartflow, INC. | $31.02 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.27 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nipun Bhandari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.